AI assistant
Oruka Therapeutics, Inc. — Director's Dealing 2012
Feb 15, 2012
32280_dirs_2012-02-14_ea320571-0ce1-4911-b601-648f64e014f3.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ARCA biopharma, Inc. (ABIO)
CIK: 0000907654
Period of Report: 2012-02-10
Reporting Person: FORMELA JEAN FRANCOIS (Director, 10% Owner)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2012-02-10 | Option to Purchase Common Stock | $1.00 | A | 3500 | Acquired | 2022-02-10 | Common Stock (3500) | Indirect |
| 2012-02-10 | Option to Purchase Common Stock | $1.00 | A | 3500 | Acquired | 2022-02-10 | Common Stock (3500) | Indirect |
Footnotes
F1: This option was granted to Jean-Francois Formela, a director of the issuer. The proceeds of any sale of the issuer's common stock issued to Dr. Formela upon the exercise of this option will be transferred to Atlas Venture Advisors, Inc. ("Atlas Advisors") and therefore Dr. Formela disclaims beneficial ownership of such shares which belong to Atlas Advisors.
F2: The options vest in 12 equal monthly installments measured from 1/1/12. If the Reporting Person's service as a director of the Issuer terminates in connection with or at anytime following a change in control (for whatever reason), then any unexpired options that remain unvested shall become fully vested.